On June 18, GenScript Biotech rose 5.41% in regular trading, trading at HK$11.82/share, with turnover of HK$92.44 million. The stock is staging a recovery after pulling back more than 9% in prior sessions on a sell-the-news reaction.

On the news front, the company's associate Legend Biotech presented first-in-class in-vivo CD19/CD20 dual-target CAR-T therapy LB2501 Phase I proof-of-concept data at the European Hematology Association annual meeting on June 14. In the ongoing Phase I study for relapsed/refractory B-cell non-Hodgkin lymphoma, a single infusion of LB2501 achieved 100% objective response rate and 83.3% complete response rate at the second dose level, with all responses ongoing at data cutoff. Notably, LB2501 achieved dose-dependent in-vivo CAR-T cell expansion without lymphodepletion. The broader life sciences sector also strengthened, with Wuxi Biologics up 3.95%, Wuxi AppTec up 4.08%, and Insilico Medicine up 6.29%, providing additional sentiment support.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)